Intensity therapeutics presents int230-6 phase 1/2 data in sarcoma and an overview of its ongoing global randomized phase 3 sarcoma trial ("invincible-3 study") in a late-breaking session at the 2024 annual connective tissue oncology society meeting (ctos)

Phase 1/2 data showed a median overall survival ("mos") of 21.3 months versus a synthetic control of 6.7 months, an increase in t-cell activation, and favorable safety profile for patients receiving int230-6 alone invincible-3 study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the invincible-3 study have been received in the u.s., canada, europe and australia shelton, conn. , nov. 18, 2024 /prnewswire/ -- intensity therapeutics, inc. (nasdaq: ints), ("intensity" or "the company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that christian f.
CTOS Ratings Summary
CTOS Quant Ranking